Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Permeability Factor in Focal Segmental Glomerulosclerosis
NCT00007475Phase 2Completed
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Dec 2000
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide in focal segmental glomerulosclerosis (FSGS), sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Primary endpoint: Reduction in Proteinuria in Recurrent FSGS Following Renal Transplant With Plasma Exchange and Cyclophosphamide. Started Dec 2000; status: completed.
02
Drugs
cyclophosphamide
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on NCT00007475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00007475.